Insulet (PODD)
(Delayed Data from NSDQ)
$171.40 USD
+2.22 (1.31%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $171.41 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth D Momentum B VGM
Insulet (PODD) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$234.94 | $270.00 | $175.00 | 38.87% |
Price Target
Based on short-term price targets offered by 17 analysts, the average price target for Insulet comes to $234.94. The forecasts range from a low of $175.00 to a high of $270.00. The average price target represents an increase of 38.87% from the last closing price of $169.18.
Analyst Price Targets (17)
Broker Rating
Insulet currently has an average brokerage recommendation (ABR) of 1.39 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 18 brokerage firms. The current ABR compares to an ABR of 1.39 a month ago based on 18 recommendations.
Of the 18 recommendations deriving the current ABR, 14 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 77.78% and 5.56% of all recommendations. A month ago, Strong Buy made up 77.78%, while Buy represented 5.56%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 14 | 14 | 14 | 14 | 14 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.39 | 1.39 | 1.39 | 1.39 | 1.39 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
2/23/2024 | Piper Sandler | Matthew O'Brien | Strong Buy | Strong Buy |
1/7/2024 | BTIG | Ryan Zimmerman | Strong Buy | Strong Buy |
12/21/2023 | Robert W. Baird & Co. | Jeffrey D Johnson | Hold | Strong Buy |
11/3/2023 | Canaccord Genuity | William J Plovanic | Not Available | Strong Buy |
10/16/2023 | SVB Securities | Michael Kratky | Not Available | Strong Buy |
10/4/2023 | William Blair | Margaret Kaczor | Strong Buy | Strong Buy |
9/15/2023 | Raymond James | Jayson T Bedford | Moderate Buy | Moderate Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.39 |
ABR (Last week) | 1.39 |
# of Recs in ABR | 18 |
Average Target Price | $234.94 |
LT Growth Rate | 18.10% |
Industry | Medical - Products |
Industry Rank by ABR | 89 of 252 |
Current Quarter EPS Est: | 0.39 |